Giovanna Ferrari

🧬 The pharma services sector is experiencing rapid growth, driven by factors such as chronic diseases, regulation and R&D. 🔗 Our 'Ones to Watch' report highlights the most successful companies contributing to life sciences and the UK economy: https://okt.to/o0dMgx #PharmaServices #LifeSciences #MandA

58

1 Comment

Merck has pulled out of a planned £1bn London drug research centre in the latest blow to the government’s growth agenda. The US pharma giant is to lay off 127 staff alongside abandoning the construction project, which had been set to open in King’s Cross in 2027. The firm warned the UK would lag behind the rest of Europe in spending on health research unless it made conditions more attractive to invest. “Unless a change is made to the operating environment, the undervaluation is corrected, and the investment is put back in the right places, more and more companies will be making these sorts of decisions,” Merck said. Read the full story here 👇 https://lnkd.in/ep45jyrG #uk #london #news #business #health #research #science #pharma #tech #economy #economics #finance #investment #politics #labourparty #merk #astrazeneca

90

2 Comments

One of the major topics facing the discussion panel at the HSJ Medicines Forum in London on the 16th October will be how NHS leaders are navigating a period of unprecedented change. With escalating financial pressures, widespread workforce reductions, and the disruptive effects of the recent NHS England reorganisation, maintaining high-quality patient care has become a significant challenge. Points for panel discussion will also include: -Financial Pressures: How are 50% ICB cost cuts affecting service delivery? -Structural Instability: What are the consequences of organisational mergers and the loss of institutional knowledge on system performance? -Workforce Morale: How are these changes impacting the morale of staff across pharmacy, commissioning, and frontline services? We're delighted to welcome Yousaf Ahmad to the panel at the forum. Yousaf will also be joined by Kandarp Thakkar and Paula Wilkinson FRPharmS to give us their unique insight into these key issues. There are just a handful of places now remaining for the HSJ Medicines Forum. To secure your place, or to find out more click here: https://lnkd.in/eSWrE4Yd #Medicines #HSJMedicines #Communitypharmacy #Pharmacy #NHS

34

With the National Cancer Plan expected in the coming months, its contents sparked discussions on the sidelines of the Labour Party Conference.   John McNeill, Oncology Business Unit Director at MSD in the UK, explores in The House Magazine how the Plan can truly improve care and outcomes for cancer patients across England.   From reducing disparity in care to preparing for the next generation of treatments, the National Cancer Plan presents a rare opportunity to address the challenges facing cancer patients in England today and enable the NHS for tomorrow.   See below three elements we believe the Plan should deliver on👇and read the full article here 👉 http://bit.ly/4ogj63z   GB-NON-11930

57

The UK’s life sciences sector is at a pivotal moment... Despite Merck’s and AstraZeneca’s recent announcements, there are reasons for optimism. The convergence of AI and health innovation is creating new opportunities for growth - especially in the spaces where universities, hospitals and investors collaborate. Our CEO, Anne Lane, has written an op-ed in the Financial Times about her optimism for the sector. She highlights that, at UCLB, we’ve seen firsthand how research breakthroughs can become commercial success stories: £3bn external in investment since 2020, and 100+ spinout companies creating 2300+ jobs.  But the potential goes far beyond this. To truly unlock economic growth, the UK needs more early-stage funding to help academic research become market-ready, more scale-up venture capital and an easier-to-access NHS, to provide the market ‘pull’ for homegrown health innovations coming out of our universities. Read Anne's thoughts on what needs to change - and why the UK can still lead the next wave of medical breakthroughs (£): https://lnkd.in/eZGYiSc7

152

1 Comment